Booklet Updates - Myeloma
The following drug updates are listed by booklet title. This information is not found in the current version of these booklets, as these treatments were not FDA approved at the time the books were published.
Myeloma
and
The Myeloma Guide: Information for Patients and Caregivers
- In April 2024, the Food and Drug Administration (FDA) updated the indication for idecabtagene vicleuce (Abecma®) to treat adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
- In April 2024, the Food and Drug Administration (FDA) updated the indication for ciltacabtagene autoleucel (Carvykti™) to treat adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
- In August 2023, the Food and Drug Administration (FDA) approved elranatamab-bcmm (Elrexfio™) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
- In August 2023, the Food and Drug Administration (FDA) approved talquetamab-tgvs (Talvey™) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.